Xerava (eravacycline) / SOM Biotech, Ewha Womans University, PAION, Everest Medicines, Innoviva - LARVOL DELTA

Real-world use of eravacycline for the treatment of mono- and polymicrobial infections involving Enterobacterales. (PubMed, Microbiol Spectr) - "Eravacycline (ERV) is a promising non-β-lactam antibiotic with a broad spectrum of activity, including methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococci, and carbapenem-resistant Enterobacterales...In this study, we assessed the safety and effectiveness of eravacycline for the treatment of Enterobacterales infections in a real-world setting. These findings suggest that eravacycline may be a viable therapeutic agent for these infections, expanding our treatment options for multidrug-resistant (MDR) pathogens."

Journal • Real-world evidence • Infectious Disease • Pneumonia • Respiratory Diseases

Antimicrobial activity of sulbactam-durlobactam against Acinetobacter baumannii-calcoaceticus complex strains causing non-respiratory and non-bloodstream infections from the United States (2023-2025). (PubMed, Microbiol Spectr) - "This study aims to evaluate the in vitro activity of sulbactam-durlobactam and comparator antibiotics, including meropenem and cefiderocol against A. baumannii-calcoaceticus complex isolates from non-respiratory and non-bloodstream sources...Minocycline susceptibility was 69.1%, while tigecycline and eravacycline MICs50/90 were 1/4 and 0.5/1 mg/L, respectively...The results are important because they can inform clinicians on the susceptibility profiles of A. baumannii from a variety of infection sources, not just lung and bloodstream. As new antibiotics come onto the market, it is important to continuously assess resistance patterns to inform patient and system-wide health decisions."

Journal • Infectious Disease • Nephrology • Pneumonia • Respiratory Diseases

Clinical efficacy and safety of eravacycline-based therapy for critically ill patients with CRAB- or CRKP-associated HAP/VAP (ESCMID Global 2026) - No abstract available

Clinical • Infectious Disease • Pneumonia • Respiratory Diseases

Comparative between eravacycline and best available therapy in carbapenem-resistant Acinetobacter baumannii HAP/VAP in China: a retrospective multi-centre cohort study (ESCMID Global 2026) - No abstract available

Retrospective data • Infectious Disease • Pneumonia • Respiratory Diseases

Effectiveness of eravacycline treatment against infection of A. baumannii and K. pneumoniae: a real-world multi-centre retrospective study (ESCMID Global 2026) - No abstract available

Real-world • Real-world evidence • Retrospective data • Infectious Disease • Pneumonia

Efficacy and safety of eravacycline treatment against various infections: a real-world multi-centre retrospective study in China (ESCMID Global 2026) - No abstract available

Real-world • Real-world evidence • Retrospective data • Infectious Disease

Real-world experience with eravacycline for the treatment of bloodstream infections (ESCMID Global 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Infectious Disease

Clinical outcomes of eravacycline in Chinese patients with Stenotrophomonas maltophilia infections: a multi-centre observational study (ESCMID Global 2026) - No abstract available

Clinical • Clinical data • Observational data • Infectious Disease

Eravacycline showed potent in vitro activity against tetracycline-resistant clinical isolates collected in a tertiary hospital in Madrid (ESCMID Global 2026) - No abstract available

Preclinical

Efficacy, safety, and population pharmacokinetics of eravacycline for carbapenem-resistant organism infections in immunocompromised hosts: a multi-centre prospective cohort study (ESCMID Global 2026) - No abstract available

Clinical • PK/PD data • Infectious Disease

PK/PD-optimised eravacycline for vancomycin-resistant Enterococcus faecium in a liver transplant recipient (ESCMID Global 2026) - No abstract available

Clinical • PK/PD data • Transplantation

MULTIDRUG-RESISTANT ACINETOBACTER SPP. BLOODSTREAM INFECTIONS IN HEMATOLOGIC PATIENTS: CLINICAL CHARACTERISTICS, GENOMIC FEATURES, AND ERAVACYCLINE-BASED COMBINATION THERAPY (EBMT 2026) - "Checkerboard assays evaluated the in vitro activity of eravacycline combined with sulbactam, meropenem, cefoperazone–sulbactam, polymyxin B, and levofloxacin. This study provides comprehensive clinical, microbiological, and genomic insights into MDR Acinetobacter spp. BSI in hematologic patients. The high mortality associated with MDR-BSI underscores the urgent need for effective therapeutic strategies."

Clinical • Combination therapy • Hematological Disorders • Infectious Disease • Neutropenia

ERAVACYCLINE IN ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS: A REAL-WORLD STUDY OF DRUG-DRUG INTERACTIONS WITH CYCLOSPORINE/TACROLIMUS AND ANTI-INFECTIVE EFFICACY (EBMT 2026) - "Eravacycline, a novel synthetic tetracycline, shares the CYP3A4 metabolic pathway with CNIs, yet comprehensive data on their potential pharmacokinetic interactions are scarce...Subgroup analysis revealed that when co-administered azoles and letermovir, no significant changes in C/D ratio were observed between pre-treatment and during treatment both in cyclosporine group (n=18) and tacrolimus group (n=7)... This study provides the first clinical evidence of pharmacokinetic interaction between eravacycline with CNIs in allo-HSCT, characterized by increased CNI exposure during eravacycline administration and delayed post-cessation exposure elevation, with this effect waning within around 2 weeks. Despite its modest magnitude, Intensified CNI monitoring and stepwise dose adjustments are recommended throughout and after eravacycline therapy, particularly for tacrolimus during eravacycline administration."

Clinical • Real-world • Real-world evidence • Acute Graft versus Host Disease • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Disorders • Infectious Disease • Transplantation • CYP3A4

MULTIDRUG-RESISTANT ACINETOBACTER SPP. BLOODSTREAM INFECTIONS IN HEMATOLOGIC PATIENTS: CLINICAL CHARACTERISTICS, GENOMIC FEATURES, AND ERAVACYCLINE-BASED COMBINATION THERAPY (EBMT 2026) - "Checkerboard assays evaluated the in vitro activity of eravacycline combined with sulbactam, meropenem, cefoperazone–sulbactam, polymyxin B, and levofloxacin. This study provides comprehensive clinical, microbiological, and genomic insights into MDR Acinetobacter spp. BSI in hematologic patients. The high mortality associated with MDR-BSI underscores the urgent need for effective therapeutic strategies."

Clinical • Combination therapy • Hematological Disorders • Infectious Disease • Neutropenia

ERAVACYCLINE IN ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS: A REAL-WORLD STUDY OF DRUG-DRUG INTERACTIONS WITH CYCLOSPORINE/TACROLIMUS AND ANTI-INFECTIVE EFFICACY (EBMT 2026) - "Eravacycline, a novel synthetic tetracycline, shares the CYP3A4 metabolic pathway with CNIs, yet comprehensive data on their potential pharmacokinetic interactions are scarce...Subgroup analysis revealed that when co-administered azoles and letermovir, no significant changes in C/D ratio were observed between pre-treatment and during treatment both in cyclosporine group (n=18) and tacrolimus group (n=7)... This study provides the first clinical evidence of pharmacokinetic interaction between eravacycline with CNIs in allo-HSCT, characterized by increased CNI exposure during eravacycline administration and delayed post-cessation exposure elevation, with this effect waning within around 2 weeks. Despite its modest magnitude, Intensified CNI monitoring and stepwise dose adjustments are recommended throughout and after eravacycline therapy, particularly for tacrolimus during eravacycline administration."

Clinical • Real-world • Real-world evidence • Acute Graft versus Host Disease • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Disorders • Infectious Disease • Transplantation • CYP3A4

Eravacycline: from clinical trials to its potential place in everyday therapy. (PubMed, Curr Opin Infect Dis) - "While clinical data remain limited, eravacycline appears promising for the treatment of infections caused by MDR pathogens, particularly in patients with limited therapeutic options or intolerance to β-lactams. As resistance mechanisms continue to evolve, the role of eravacycline in real-world clinical practice may extend beyond its current indications, warranting further research to define its optimal therapeutic applications."

Journal • Review • Infectious Disease • Pneumonia • Respiratory Diseases

Study on the Decontamination Effect of Eravacycline on Multidrug-Resistant Bacteria in Hypothermic Organ Preservation Solution. (PubMed, Microb Drug Resist) - "Eravacycline (ERV), a novel tetracycline antibiotic, shows potent activity against MDRB, but its efficacy in hypothermic PS (0°C-4°C) is unverified. These findings indicate that eravacycline exhibits strain-dependent antibacterial activity in hypothermic preservation solution, with 50 mg/L being effective against most tested multidrug-resistant organisms except carbapenemase-negative P. aeruginosa. Further clinical studies are warranted to evaluate its potential application in transplantation settings."

Journal • Infectious Disease • Pneumonia • Transplantation

Access to New Antibacterials in 10 Asian Countries: an Asian Network for Surveillance of Resistant Pathogens study. (PubMed, Int J Antimicrob Agents) - "Access to NME antibacterials in Asia remains markedly limited, with substantial approval delays. Considering the severity of antimicrobial resistance in the region, concerted efforts are warranted to improve access to crucial antibiotics in Asia."

Journal

Analysis of the evolution mechanism of in-host drug resistance of Klebsiella pneumoniae during treatment with tigecycline, eravacycline and Polymyxin B. (PubMed, Ann Clin Microbiol Antimicrob) - "It was found that d5 and d15 were sensitive to Polymyxin B, while strains d13, d17 and d21 were resistant to Polymyxin B. The results of drug sensitivity were consistent with the expression level of the colistin resistance gene pmrB and also consistent with the SNP difference results of pmrB in these five strains. It was found that position 523 on the ABC efflux pump system mutated from Ala to Thr, suggesting that the evolution of drug resistance of tigecycline and eravacycline may be related to the ABC efflux pump. The results indicated that Klebsiella pneumoniae witnessed the evolution of drug resistance in the host during the treatment with Polymyxin B, eravacycline and tigecycline, posing a potential threat to clinical anti-infective treatment."

Journal • Fibrosis • Gastroenterology • Hepatology • Immunology • Infectious Disease • Liver Cirrhosis • Liver Failure • Pneumonia

Efficacy and Safety of Eravacycline in Lung Transplant Recipients With Multidrug-Resistant Bacteria Infection: A Single-Arm Retrospective Study (ATS 2026) - No abstract available

Retrospective data • Infectious Disease • Transplantation

In vitro activity of recently introduced Gram-positive-specific antimicrobial agents against Australian methicillin-resistant Staphylococcus aureus isolates. (PubMed, Pathology) - "MIC was determined for ceftaroline, ceftobiprole, tedizolid, dalbavancin, eravacycline, omadacycline, delafloxacin, lefamulin and vancomycin. Susceptibility testing prior to use of delafloxacin, lefamulin and omadacycline should be considered. When the use of these agents becomes commonplace, ongoing monitoring for resistance is recommended."

Journal • Preclinical • Infectious Disease • Pneumonia • Respiratory Diseases

Antimicrobial Susceptibility of Clostridioides difficile in Spain: Multicenter Retrospective Cohort Study. (PubMed, Antibiotics (Basel)) - P | "Background/Objetives: The objective of this study was to determine the in vitro susceptibility profiles of clinical Clostridioides difficile isolates to metronidazole (MTZ), vancomycin (VAN), fidaxomicin (FDX), tigecycline (TGC), and eravacycline (ERV) in a multicenter Spanish cohort, and to evaluate their association with clinical factors. Resistance to MTZ, VAN, and TGC was uncommon but detectable. Findings highlight the need for continued antimicrobial resistance surveillance and evaluation of its potential clinical impact."

Journal • Retrospective data • Infectious Disease

Phenotypic and Molecular Characterization of Clinical Isolates of Vancomycin-Resistant Enterococcus faecium in the Health District of Bolzano (Italy) During 2021-2023. (PubMed, Pathogens) - "Isolates showed high antibiotic resistance to various antibiotics, but generally remained susceptible to quinupristin/dalfopristin, tigecycline and eravacycline. Genomic analysis of the ST80 isolates showed that nearly all of them belonged to a single cluster. To prevent further spread of VREfm in the nosocomial environment, in addition to the application of up-to-date infection control strategies and antibiotic stewardship programs, the implementation of genomic surveillance is recommended."

Journal • Infectious Disease

Stepwise Evolution of Triple Antimicrobial Resistance in Neisseria meningitidis. (PubMed, J Infect Dis) - "We report the first identification of N. meningitidis with concurrent resistance to penicillin, ciprofloxacin, and tetracycline, mediated by blaROB-1, gyrA T91I, and tetB, representing a critical escalation in meningococcal antimicrobial resistance."

Journal • Infectious Disease • Meningococcal Infections

Therapeutic effect of eravacycline against carbapenem-resistant hypervirulent Klebsiella pneumoniae in mouse models. (PubMed, Antimicrob Agents Chemother) - "This study aims to investigate the therapeutic effect of a novel tetracycline antibiotic, eravacycline, on CR-hvKP pneumonia. Notably, eravacycline suppressed the mRNA expression of STAT1 and p-STAT1 activation in the lung tissue of mice in the treatment group. In conclusion, clinical isolates KP78, KP98, and KP100 caused severe lung injury after invading mouse lung tissues, and eravacycline attenuated the lung injury and inflammatory response induced by CR-hvKP invasion."

Journal • Preclinical • Infectious Disease • Inflammation • Pneumonia • Respiratory Diseases • IL1B • IL6